Showing results (91-100 of 280) with videos related to

Sort By:
Pageof 28
Avicenna Journal of Medicine|October 16, 2018
Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital settingHarry Menon, Adip Pillai, Jeanine Aussenberg-Rodriguez, et al.
Expert Opinion on Orphan Drugs|August 8, 2019
Bosutinib for the Treatment of Philadelphia Chromosome-Positive LeukemiasCristina Varallo-Rodriguez, Craig W Freyer, Evelena P Ontiveros, et al.
Leukemia Research Reports|September 3, 2014
High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failureMorgan B Smith, Elizabeth A Griffiths, James E Thompson, et al.
Leukemia & Lymphoma|October 30, 2004
Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemiaRobert Z Orlowski, Sharon R Mills, Eric E Hartley, et al.
Plos One|August 22, 2015
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic MalignanciesEric Laille, Tao Shi, Guillermo Garcia-Manero, et al.
Haematologica|January 3, 2012
Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromesAmy J Davidoff, Sheila Weiss Smith, Maria R Baer, et al.
Leukemia Research|April 15, 2015
Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact responseVu H Duong, Maria R Baer, Franklin Hendrick, et al.
Blood Advances|August 2, 2022
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyureaRong Wang, Rory M Shallis, Jessica M Stempel, et al.
Leukemia & Lymphoma|April 26, 2021
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United StatesXiaoyi Wang, Amer M Zeidan, Rong Wang, et al.
Health and Quality of Life Outcomes|August 9, 2024
Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational studyElizabeth A Griffiths, Jae S Min, Wei-Nchih Lee, et al.
Pageof 28